REG - Verici Dx PLC - Board Change

Verici DxAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe7127Ya&default-theme=true

RNS Number : 7127Y  Verici Dx PLC  31 March 2026

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Board Change

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that James McCullough, Non-Executive Director, has
resigned from the Board with immediate effect to focus on his role as CEO of
Renalytix plc.

 

The Company has begun its search for a replacement Non-Executive Director to
join the Board and will provide an update in due course.

 

Sara Barrington, Chief Executive Officer, said: "It has been a pleasure to
work alongside James for the last five years and I would like to thank James
for his expertise, advice and contribution to the Company. I wish James every
success and all the best for the future."

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker)                     Tel: +44 (0)20 7496 3000
 Phil Davies

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Rachel Broad                 Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393

 

 

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care
for transplant patients. The company combines multiomic analysis with
proprietary artificial intelligence to deliver predictive, actionable,
data-driven intelligence that reflects the complexity and heterogeneity of
transplant patients, enabling clinicians to optimize therapy, guide biopsy
decisions, and stratify risk with greater confidence.

 

Operating at the intersection of laboratory and data science, Verici Dx
develops complex models that answer the clinical questions that matter most
with unrivaled clarity and precision. All tests are built to rigorous
scientific standards, validated across inclusive, and real-world patient
populations to ensure clinical relevance and reliability. Verici Dx's lead
product, Tutivia™, is a post-kidney transplant test focused on early
detection of acute rejection.

 

The company is UK headquartered in Cardiff for the UK, and in Franklin,
Tennessee for the U.S. For more information, please visit
https://vericidx.com/ (https://vericidx.com/) and follow us on LinkedIn
(https://www.linkedin.com/company/verici-dx/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKBLFXQXLLBBZ



            Copyright 2019 Regulatory News Service, all rights reserved